Santiago Viteri, Medical Director at UOMi Cancer Center and Chief Executive Officer at Pratia Sirius, reshared a post on LinkedIn by International Association for the Study of Lung Cancer adding:
“Negative results communication is key to having a better understanding od scientific problems.
As an investigator of the BR.31 trial, I am happy to contribute to evaluate the effect of adjuvant antiPD1 in non-small cell lung cancer (NSCLC).”
Quoting International Association for the Study of Lung Cancer’s post:
“Check out the latest findings from the BR.31 trial that were presented at the 2024 ESMO Congress.
Visit ILCN for a recap.”
For more updates, follow OncoDaily.